Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: A Multicenter, Open-Label Trial

Systemic Lupus Erythematosus

Systemic lupus erythematosus-disease activity score remission and low disease activity were similarly associated with patient-reported outcomes compared with definition of remission in systemic lupus erythematosus remission and lupus low disease activity state

Rheumatology (Oxford)

Nakanishi E, Matsushita M, Minowa K, Tada K, Kawamoto T, Kusaoi M, Amano H, Kon T, Morimoto S, Ikeda K, Suzuki S, Nozawa K, Yang KS, Matsudaira R, Katagiri A, Tsushima H, Urasaki W, Nojiri S, Yamaji K, Tamura N

doi: 10.1093/rheumatology/keaf349

Systemic Lupus Erythematosus

Enhancing systemic lupus erythematosus treatment outcomes with an early initiation of belimumab: insights from a multicenter retrospective study within the first five years

Arthritis Res Ther

Kojima K, Ichinose K, Umeda M, Shimizu T, Sato S, Suzuki T, Nakashima Y, Okada A, Horai Y, Fujikawa K, Aramaki T, Miyashita T, Furuyama M, Matsuoka N, Kawakami A

doi: 10.1186/s13075-025-03581-0

Systemic Lupus Erythematosus

LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trials

Ann Rheum Dis

Morand EF, van Vollenhoven R, Furie RA, Kalunian KC, Manzi S, Abreu G, Tummala R, Duncan EA, Al-Mossawi H, Lindholm C

doi: 10.1016/j.ard.2025.01.016

Acne

Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension

J Am Acad Dermatol

Sayed CJ, Kirby B, Garg A, Naik HB, Kimball AB, Zouboulis CC, Jemec GBE, Kokolakis G, Ingram JR, Morita A, Deherder D, Crater C, Rolleri RL, Vaux T, Lambert J, Lukowski B, Bechara FG

doi: 10.1016/j.jaad.2025.11.031

Systemic Lupus Erythematosus

Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): results of a prospective, single-arm, open-label, phase 2 trial

Ann Rheum Dis

Branch DW, Kim MY, Guerra MM, Worden J, Laskin CA, DeSancho MT, Landres IV, Knight JS, Slosberg HS, Minett M, Salmon JE

doi: 10.1016/j.ard.2025.02.012

Systemic Lupus Erythematosus

A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus

N Engl J Med

van Vollenhoven RF, Wang L, Merrill JT, Liu Y, Bao C, Li F, Hu J, Huang C, Zhao J, Huang C, Mo H, Wei W, Lu F, Li J, Zhao D, Wang W, Li L, Zuraw Q, Wang X, Wang X, Fang J, Zhang F, 18C010 Trial Investigators

doi: 10.1056/NEJMoa2414719

Systemic Lupus Erythematosus

A Pediatric-Adult Provider Dyad Care Model Improves Transition From Pediatric to Adult Healthcare For Youth with Childhood-onset Systemic Lupus Erythematosus

J Rheumatol

El Tal T, Steiman A, Knight A, Hiraki LT, Levy DM, Toulany A, Silverman ED

doi: 10.3899/jrheum.2025-0046

Immunodeficiency

A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary Immunodeficiency

J Clin Immunol

Lumry WR, Palumbo M, Hsu C, Hussain I, McNeil D, Bridges T, Wedner HJ, Scarupa M, Mondou E, Nanaware-Kharade N, Hanna K, Coll MQ, Oliveras J

doi: 10.1007/s10875-025-01952-5

Systemic Lupus Erythematosus

Individual and Socio-ecological Resilience in Childhood-Onset Systemic Lupus Erythematosus: Associations with Patient Characteristics and Psychosocial Patient-Reported Outcomes

J Rheumatol

Zaffino I, Boulard L, Law J, Danguecan A, Jeyanathan A, Ng L, Williams-Reid S, Reid K, Cortes A, Cortes E, Levy DM, Hiraki LT, Knight AM

doi: 10.3899/jrheum.2025-0375

Related content

Systemic lupus erythematosus-disease activity score remission and low disease activity were similarly associated with patient-reported outcomes compared with definition of remission in systemic lupus erythematosus remission and lupus low disease activity state

Enhancing systemic lupus erythematosus treatment outcomes with an early initiation of belimumab: insights from a multicenter retrospective study within the first five years

LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trials

Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension

Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): results of a prospective, single-arm, open-label, phase 2 trial

A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus

A Pediatric-Adult Provider Dyad Care Model Improves Transition From Pediatric to Adult Healthcare For Youth with Childhood-onset Systemic Lupus Erythematosus

A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary Immunodeficiency

Individual and Socio-ecological Resilience in Childhood-Onset Systemic Lupus Erythematosus: Associations with Patient Characteristics and Psychosocial Patient-Reported Outcomes